Verrica Pharmaceuticals Inc.VRCAEarnings & Financial Report
Verrica Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative prescription treatments for common and rare dermatological conditions. It primarily serves North American patients and healthcare providers, delivering solutions for unmet needs in dermatology care.
VRCA Q3 FY2025 Key Financial Metrics
Revenue
$14.3M
Gross Profit
N/A
Operating Profit
$1.6M
Net Profit
$-274.0K
Gross Margin
N/A
Operating Margin
11.3%
Net Margin
-1.9%
YoY Growth
905.4%
EPS
$-0.03
Verrica Pharmaceuticals Inc. Q3 FY2025 Financial Summary
Verrica Pharmaceuticals Inc. reported revenue of $14.3M (up 905.4% YoY) for Q3 FY2025, with a net profit of $-274.0K (up 98.8% YoY) (-1.9% margin).
Key Financial Metrics
| Total Revenue | $14.3M |
|---|---|
| Net Profit | $-274.0K |
| Gross Margin | N/A |
| Operating Margin | 11.3% |
| Report Period | Q3 FY2025 |
Revenue Breakdown
Verrica Pharmaceuticals Inc. Q3 FY2025 revenue of $14.3M breaks down across 2 segments, led by License And Collaboration Revenue at $10.7M (74.9% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| License And Collaboration Revenue | $10.7M | 74.9% |
| Products | $3.6M | 25.1% |
Verrica Pharmaceuticals Inc. Revenue by Segment — Quarterly Trend
Verrica Pharmaceuticals Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as License And Collaboration Revenue and Products) has evolved quarter over quarter.
| Segment | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024 |
|---|---|---|---|---|
| License And Collaboration Revenue | $10.7M | $8.2M | — | — |
| Products | $3.6M | $4.5M | — | — |
Verrica Pharmaceuticals Inc. Annual Revenue by Year
Verrica Pharmaceuticals Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $7.6M).
Verrica Pharmaceuticals Inc. Quarterly Revenue & Net Profit History
Verrica Pharmaceuticals Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $14.3M | +905.4% | $-274.0K | -1.9% |
| Q2 FY2025 | $12.7M | +145.4% | $204.0K | 1.6% |
| Q1 FY2025 | $3.4M | -10.1% | $-9.7M | -283.3% |
| Q4 FY2024 | $344.0K | -82.7% | N/A | N/A |
| Q3 FY2024 | $-1.8M | -161.1% | $-22.9M | 1283.5% |
| Q2 FY2024 | $5.2M | +2744.5% | $-17.2M | -332.0% |
| Q1 FY2024 | $3.8M | +10240.5% | $-20.3M | -531.4% |
| Q4 FY2023 | $2.0M | +2823.5% | $-24.6M | -1238.1% |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0M | $3.8M | $5.2M | $-1.8M | $344000 | $3.4M | $12.7M | $14.3M |
| YoY Growth | 2823.5% | 10240.5% | 2744.5% | -161.1% | -82.7% | -10.1% | 145.4% | 905.4% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $81.6M | $66.3M | $52.0M | $32.9M | $54.1M | $42.2M | $39.1M | $40.9M |
| Liabilities | $61.8M | $64.8M | $65.3M | $67.0M | $64.0M | $60.8M | $56.6M | $57.9M |
| Equity | $19.8M | $1.5M | $-13.3M | $-34.1M | $-9.9M | $-18.6M | $-17.5M | $-17.0M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-14.5M | $-19.9M | $-16.4M | $-8.6M | $-60.9M | $-12.7M | $-10.0M | $9.7M |